Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Document › Details

Themis Bioscience N.V.. (11/8/18). "Press Release: Themis Bioscience Postpones Its Listing on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna.

	Region	Amsterdam
	Country	Netherlands
	Organisation	Themis Bioscience N.V.
	Organisation 2	Euronext Amsterdam N.V.
	Group	Euronext (Group)
	Product	Measles Vector (MV) technology platform
	Product 2	investment banking
	Index term	Themis Bioscience–SEVERAL: investment, 201810– IPO €35m to €55.3m on Euronext Amsterdam POSTPONED 11/18

Original document
accessed by [iito] on 2018-11-11

Record changed: 2023-06-05

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Merck (US) (MSD) (Group)

[1] Anavo Therapeutics B.V.. (5/2/23). "Press Release: Anavo Therapeutics Extends Seed Round to EUR 28 Million to Advance Pipeline of Novel Phosphatase Modulators Toward the Clinic". Leiden & Heidelberg....
[2] Biognosys AG. (6/17/20). "Press Release: Biognosys Announces Appointment of Dr. Patrick Vink as Chairman". Schlieren....
[3] iTeos Therapeutics S.A.. (12/12/19). "Press Release: iTeos Therapeutics Announces Collaboration with Merck Investigating the Combination of its A2A Antagonist with Keytruda". Gosselies & Cambridge, MA....
[4] Themis Bioscience GmbH. (10/29/19). "Press Release: Themis Bioscience and CEPI Announce Initiation of Phase 1 Clinical Trial with Lassa Fever Vaccine". Vienna & Oslo....
[5] Themis Bioscience N.V.. (10/29/18). "Press Release: Themis Bioscience Launches its Initial Public Offering on Euronext Amsterdam [Not for United States, Canada, Australia or Japan or any other jurisdiction where unlawful]". Vienna....
[6] Noxxon Pharma N.V.. (6/15/18). "Press Release: Noxxon Announces that It Has Secured Additional Financing". Berlin....
[7] Noxxon Pharma N.V.. (9/28/17). "Press Release: Noxxon Provides Update on Ongoing Phase 1/2 Clinical Trial with Lead Program NOX-A12". Berlin....
[8] Merck & Co., Inc.. (9/6/17). "Press Release: Merck to Acquire Rigontec, RIG-I Therapeutics Pioneer, Advancing Leadership in Immuno-Oncology". Kenilworth, NJ & Munich....
[9] Complix N.V.. (7/27/17). "Press Release: Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies". Hasselt....
[10] Ablynx N.V.. (6/27/17). "Press Release: Ablynx Achieves Second Milestone in Immuno-oncology Collaboration with Merck & Co., Inc., Kenilworth, New Jersey, USA". Ghent....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)